Name	Dan S. Kaufman, MD, PhD
Current Position	Professor of Medicine
Country	United States of America
Major Field	Immunology

Educational Background

Undergraduate Education: Stanford University, Stanford, CA. 1984-1988.
B.S. in Biological Sciences (with departmental honors).
Medical School: Mayo Medical School, Rochester, MN, 1989-1996. Combined MD/PhD program.
Graduate School: Mayo Graduate School, Rochester, MN, 1991-1994.
Ph.D. in Immunology. Thesis: Influence of MHC Class I Recognition on Natural Killer Cell Activation. Thesis advisor: Paul J. Leibson, MD, PhD.

Residency: Dept. of Internal Medicine, U. of Wisconsin- Madison, WI, 1996-1999.

Fellowship:
Dept. of Internal Medicine, Section of Hematology/BMT, University of Wisconsin Hospital and Clinics, Madison, WI. 1999-2002.

Post-Doctoral Research:
Hematopoietic and endothelial cell development from embryonic stem cells. U. of Wisconsin-Madison. Advisors: James Thomson, VMD, PhD, and Robert Auerbach, PhD. 1999-2002.

Professional Experience

2020 - Vice Chief, Division of Regenerative Medicine, University of California- San Diego
2016 - Director of Cell Therapy Program, University of California- San Diego.
2016 - Professor, Dept. of Medicine, Division of Regenerative Medicine, University of California- San Diego.
2016 - Scientific and Medical Director, University of California-San Diego Advanced Cell Therapy Laboratory.
2002-2016 Asst., Assoc., then Professor of Medicine, Division of Hematology, Oncology, and Transplantation. University of Minnesota, Minneapolis, MN.
2011- 2016 Co-director, Center of Cellular Therapy and Regenerative Medicine, Brno, Czech Republic.

Other Experience and Professional Memberships

Professional Society Memberships:
American Society of Hematology (ASH), 2000-present.
American Society for Blood and Marrow Transplantation (ASBMT), 2001-present.
International Society for Experimental Hematology (ISEH), 2001-present.
International Society for Stem Cell Research (ISSCR), 2003- present.
American Society for Clinical Investigation (ASCI), 2009- present.
American Association for Cancer Research (AACR), 2017- present.
Society for Natural Immunity (SNI), 2019-present.

Professional Activities:
Member, Scientific Committee on Stem Cells. American Society for Cell and Gene Therapy (ASGCT). 2022-present.
Vice Chair then Chair American Society of Hematology (ASH) Scientific Committee on Stem Cells and Regenerative Medicine. 2017-2018.
NIH Study Section on Cellular Mechanisms of Aging and Development (CMAD), Regular member. 2013-2017
International Society for Stem Cell Research (ISSCR) Membership Committee. 2013-2022.
International Society for Stem Cell Research(ISSCR) Committee on Stem Cell Standards. 2008-2011

Main Scientific Publications

Bernareggi, D. , Xie, Q., Prager, BC., Yun, J., Cruz, LS., Pham, TV., Kim, W., …Tamayo, P., Rich, JN., and **Dan S. Kaufman.** CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity. *Nature Communications* (2022). 13, 1899.

Hanh, WC...**Kaufman, DS**... Gerhard DS. Cancer Target Discovery and Development Network (CTD2). An expanded universe of cancer targets. *Cell.* (2021). 184:1142-1155.

Zhu H, Blum R, Bernareggi D, Ask EH, Wu Z, Hoel HJ, Meng Z, Wu C, Guan KL, Malmberg KJ, **Kaufman DS**. (2020). Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity. *Cell Stem Cell*. 27: 224-237.

Zhu H, Blum R, Bjordahl R, and **Dan S. Kaufman**. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved anti-tumor activity. *Blood* (2020) **135**: 399-410.

Li, Ye, David Hermanson, Branden Moriarity, and **Dan S. Kaufman.** Engineering Human Induced Pluripotent Stem Cell-Derived Natural Killer Cells with Novel Chimeric Antigen Receptors to Enhance Anti-Tumor Activity. *Cell Stem Cell.* (2018). 23, 181-192.

Angelos MG, Ruh PN, Webber BR, Blum RH, Ryan CD, Bendzick L, Shim S, Yingst AM, Tufa DM, Verneris MR, **Kaufman DS**. Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells. *Blood* (2017). 129: 3428-3439.

Ye L, Chang YH, Xiong Q, Zhang P, Zhang L, Somasundaram P, Lepley M, Swingen C, Su L, Wendel JS, Guo J, Jang A, Rosenbush D, Greder L, Dutton JR, Zhang J, Kamp TJ, **Kaufman DS**, Ge Y, Zhang J. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. *Cell Stem Cell.* (2014).15:750-61.

Knorr, David A., Zhenya Ni, Melinda K. Hexum, Laura Bendzick, Laurence J. N. Cooper , Dean A. Lee, and **Dan S. Kaufman**. Clinical Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells For Cancer Therapy. *Stem Cells Translational Medicine*. (2013). 2:274-83.

Woll, Petter S. Bartosz Grzywacz, Xinghui Tian, Rebecca Marcus, Michael R. Verneris and **Dan S. Kaufman.** Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. *Blood*. (2009).113: 6094-6101.

Flynn C and **Kaufman DS**. Donor Cell Leukemia: Insight into cancer stem cells and the stem cell niche. *Blood.* (2007). 109: 2688-2692.

Woll PS, Martin CH, Miller JS, and **Kaufman DS. (**2005). Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. *J. of Immunology*. 175: 5095-5103.

Kaufman DS, Lewis RL,Hanson ET, Auerbach R, Plendl J, Thomson JA. Functional Endothelial Cells Derived from Rhesus Monkey Embryonic Stem Cells. *Blood*. (2004). 103: 1325-1332.

Kaufman, Dan S., E.T. Hanson, R.L. Lewis, R. Auerbach, and J.A. Thomson. Hematopoietic colony-forming cells derived from human embryonic stem cells. *Proc. Natl. Acad. Sci. USA*. (2001). 98:10716-10721.